Alterity Therapeutics Limited

ATH

AU0000043945

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:49 02/07/2024 am IST			5-day change	1st Jan Change
0.004 ^AUD	-20.00%		-11.11%	-42.86%

08/05	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	CI
08/05	Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	MT

Alterity Therapeutics Limited Announces Resignation of David Sinclair as Non-Executive Directors

January 04, 2022 at 11:24 am IST

Alterity Therapeutics announced that Non-Executive Directors Dr. David Sinclair and Mr. Tristan Edwards have resigned from the company due to competing priorities with immediate effect.

Latest news about Alterity Therapeutics Limited

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	08/05	CI
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	08/05	MT
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	29/04	CI
ADRs End Lower, Purple Biotech Ltd. Declines 29%	17/04	DJ
ADRs End Lower, Leju Holdings Ltd. Declines 72%	13/04	DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	12/04	DJ
ADRs Close Lower; VIA Optronics AG Declines 30%	11/04	DJ
Top Midday Gainers	10/04	MT
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	26/03	MT
Genetic Technologies Appoints CFO	25/03	MT
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02	CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	28/02	CI
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	23/02	MT
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06/02	CI
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	06/02	MT
Alterity Therapeutics Completes Securities Purchase Plan	02/02	MT
Alterity Dispatches Documents Of Planned Share Sale	10/01	MT
Alterity Therapeutics Concludes Second Tranche of Placement of AU$3.5 Million; Shares Plunge 20%	08/01	MT
Alterity Therapeutics to Raise Up to AU$2 Million Via Share Purchase Plan	29/12	MT
Transcript : Alterity Therapeutics Limited - Shareholder/Analyst Call	29/12
Alterity Therapeutics Names Phillip Hains as Chief Financial Officer	21/12	MT
Alterity Therapeutics Limited Announces CFO Changes	21/12	CI
ADRs End Lower; Evaxion Biotech Declines 27%	06/12	DJ
Transcript : Alterity Therapeutics Limited - Special Call	06/12
Top Premarket Decliners	05/12	MT

Chart Alterity Therapeutics Limited

Duration

Period

More charts

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Sector

Biotechnology & Medical Research

Calendar

27/02/2025 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALTERITY THERAPEUTICS LIMITED	-42.86%	17.43M
MODERNA, INC.	+16.03%	44.44B
IQVIA HOLDINGS INC.	-9.46%	37.99B
LONZA GROUP AG	+37.52%	37.75B
ALNYLAM PHARMACEUTICALS, INC.	+28.91%	30.78B
CELLTRION, INC.	-8.64%	27.38B
ICON PUBLIC LIMITED COMPANY	+12.61%	26.17B
UNITED THERAPEUTICS CORPORATION	+44.62%	14.15B
MEDPACE HOLDINGS, INC.	+34.16%	12.59B
BIO-TECHNE CORPORATION	-6.68%	11.28B

Other Biotechnology & Medical Research